Prucalopride
Intestinal Disorder
University of British ColumbiaSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 89/ 100
Competitive context
2 Active assets in the Intestinal Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
pf-08634404 Pfizer | Phase 3 | B |
Capecitabine Zhejiang University | Phase 2 | B |
Eloxatin Zhejiang University | Phase 2 | B |
Catequentinib Zhejiang University | Phase 2 | B |
ALECTINIB Hoffmann-La Roche | Phase 2 | CCC |
Oxodotreotide Sociedad Española de Medicina Nuclear e Imagen Molecular | D |
Same molecule, other indications
Prucalopride is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →